Immuneering Corporation Secures $25 Million in Private Placement to Advance Cancer Treatment Efforts
Immuneering Corporation has secured a $25 million private placement through the sale of 6,329,113 shares of Class A common stock at $3.95 each, along with warrants for an additional 2,848,096 shares at $5.50 per share. This funding will support the development of their cancer treatment, atebimetinib. The transaction is expected to close around August 26, 2025, pending customary conditions.
Immuneering Corporation, a clinical-stage oncology company, has announced a definitive securities purchase agreement for a private placement expected to generate approximately $25 million in gross proceeds. This transaction involves the sale of 6,329,113 unregistered shares of Class A common stock at $3.95 per share, alongside purchase warrants for an additional 2,848,096 shares at an exercise price of $5.50 per share. The purchase price represents a 15% premium over the company’s last reported closing price. The funds will support the continued development of Immuneering’s innovative cancer treatments, particularly their Deep Cyclic Inhibitor, atebimetinib. The closing of the private placement is contingent upon customary conditions and is anticipated to occur on or about August 26, 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-081995), on August 25, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
